AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

24 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

21 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

07 Sep 2023 07:03:16 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

12 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

07 Jul 2023 07:00:53 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

30 Jun 2023 16:02:39 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

28 Jun 2023 09:28:25 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

27 Jun 2023 20:24:44 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

01 Jun 2023 07:00:30 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

30 May 2023 07:00:54 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

08 May 2023 07:00:16 By Nasdaq GlobeNewswire